Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
MARBOFLOXACIN
Vetoquinol Ireland Limited
QJ01MA93
MARBOFLOXACIN
50 Milligram
Bolus
POM
Bovine
Marbofloxacin
Antibacterial
Authorised
1999-08-23
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocyl Bolus 50 mg Tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 3 PHARMACEUTICAL FORM Tablet. Off white bolus shaped convex tablet. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (neonatal calves). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Marbocyl bolus is indicated in the treatment of neonatal gastroenteritis caused by _Escherichia coli_, in calves of 25-50 kg. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Do not exceed the recommended duration of treatment (3 days) Each tablet contains: ACTIVE SUBSTANCE: Marbofloxacin 50.00 mg For a full list of excipients, see section 6.1 HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 19/10/2016_ _CRN 7023455_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS When administration is carried out using an applicator, care should be taken to avoid soft tissue injury. Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS People with known hypersensitivity to fluoroquinolone Read the complete document